Allergan profit falls as Botox sales slump
Thursday, 28 April, 2005
Drugmaker Allergan said quarterly net earnings fell slightly, and sales of Botox missed analyst forecasts, sending shares down 2 per cent.
First-quarter profit was US$79.9 million, or 60 cents per share, compared with $80.8 million or 60 cents per share a year earlier.
Net sales rose to $527 million, from $472 million in the year earlier period.
Botox sales were $176 million, about $10 million short of analyst views.
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
